Rimonci
Overview
Rimonci Capital is a venture capital firm focused on visual science innovation, investing in early-stage companies in ophthalmology, optometry, and neuro-ophthalmology across the U.S., Israel, Europe, and Greater China. Founded in 2016, it supports advancements in medical and IT solutions, leveraging its expertise and ecosystem to drive clinical and commercial success in the visual science field.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| TECLens, Inc. | Feb 2025 | Series A | Co-investor |
| Galimedix Therapeutics | Jan 2019 | Seed | Co-investor |
| EyeYon Medical | Mar 2021 | Series C | Co-investor |
| Taizhou Baiying Biotechnology | Jul 2018 | Angel | Co-investor |
| NovaSight | Jul 2020 | Series A | Lead |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Rimonci based?
Rimonci is headquartered in Beijing, Beijing, China.
When was Rimonci founded?
Rimonci was founded in 2016.
How many portfolio companies does Rimonci have?
Rimonci has 6 portfolio companies in Caplight's dataset.
What are some companies in Rimonci's portfolio?
Portfolio companies visible on Caplight include TECLens, Inc., Galimedix Therapeutics, EyeYon Medical, Taizhou Baiying Biotechnology, NovaSight.
What was Rimonci's most recent investment shown here?
Rimonci's most recent investment in this portfolio sample was in TECLens, Inc. in 2025.
What sectors does Rimonci focus on?
Rimonci focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Rimonci focus on?
Rimonci typically invests at the Early stage.
What is Rimonci's AUM?
Rimonci's assets under management are estimated between $0.0 and $50.0M.